Literature DB >> 16221511

Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children.

Pannipa Chulasugandha1, Pakamatz Khawplod, Piyalamporn Havanond, Henry Wilde.   

Abstract

Thailand is a canine rabies endemic country with an annual prevalence above 1,000 reported animals diagnosed rabid . Over 345,000 humans are treated for possible rabies exposures annually . Lack of perception of the disease burden, social, cultural and traditional beliefs play an important role in the failure of canine rabies control. It is unfortunate that health care budgets are increasingly allocated to human post-exposure treatment rather than to the eradication of rabies in the canine animal vector. Children under the age of 15 years represent up to one-half of dog bite victims and of human rabies deaths, but accurate data of dog bite prevalence are not available . Large scale pre-exposure immunization of children has been advocated but financial and logistic barriers have hindered implementation. This study analyzes direct medical costs of pre-exposure vaccination (PREP) as a human rabies preventive strategy, against the cost of post-exposure prophylaxis (PEP) in Thai children. Three pre- and post-exposure vaccine regimens are in use and this impacts on cost calculations. It was found that costs of both strategies, PREP of children or PEP of exposed, become equal when the dog bite incidence is 2-30%; depending on which post-exposure treatment regimens (PEP) are used.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221511     DOI: 10.1016/j.vaccine.2005.03.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  High level expression of a functionally active cholera toxin B: rabies glycoprotein fusion protein in tobacco seeds.

Authors:  Siddharth Tiwari; Devesh K Mishra; Sribash Roy; Ankit Singh; P K Singh; Rakesh Tuli
Journal:  Plant Cell Rep       Date:  2009-10-10       Impact factor: 4.570

3.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

Review 4.  Intradermal vaccination for infants and children.

Authors:  Akihiko Saitoh; Yuta Aizawa
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

5.  Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice.

Authors:  Jung-Eun Park; Hyun-Jin Shin
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

6.  Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries.

Authors:  Katie Hampson; Sarah Cleaveland; Deborah Briggs
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08

7.  Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.

Authors:  Y Bui; M Sow; E Cambron-Goulet; E Levac; F Milord
Journal:  Can Commun Dis Rep       Date:  2015-03-05

8.  Development in Immunoprophylaxis against Rabies for Animals and Humans.

Authors:  Sukdeb Nandi; Manoj Kumar
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

9.  Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province.

Authors:  Han Si; Zhong-Min Guo; Yuan-Tao Hao; Yu-Ge Liu; Ding-Mei Zhang; Shao-Qi Rao; Jia-Hai Lu
Journal:  BMC Infect Dis       Date:  2008-08-21       Impact factor: 3.090

10.  Epidemiological characteristics of human rabies in Henan province in China from 2005 to 2013.

Authors:  Guo Wei Li; Qiao Ge Chen; Zhen Yu Qu; Yao Xia; Alfred Lam; Ding Mei Zhang; Jia Hai Lu
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.